John. Thanks,
reported As mentioned our a Supply application reflect July XX, of now. XXXX The December the the months the is Services on retrospective activities briefly which months of as results prior XXX, the John new reported six three comparator where modified standard standard the the ASC adoption It the growth were and of reported customers results the the the for as new three the standard, guidance basis six segment, Clinical especially revenue company from sourcing ended XXXX method. for prepared the XX, now important, the under earlier, compared the contracted changed using adopted treatment XXXX and our concerning X, December are a of to ended XXX. results standard, net discuss accounting new related to of prior-year basis I ASC while in
to more Softgel business. segment for turn our beginning slide a on please detailed with discussion Now, X performance,
will earnings As commentary be in around currency. growth past in segment calls, my constant
of the million. to segment segment X% EBITDA negatively revenue declining the declined ibuprofen quarter, approximately during X% $X EBITDA of impacted health which due consumer Softgel worldwide million by lower a volume with $XXX.X shortage, result as
experienced information we available, ibuprofen in until latest as strength expect continue the noted the headwind higher Given by for and have health the the worldwide offset for stabilizes, we where Europe earlier. next prescription to This consumer partially we shortage products. supply quarter John was demand
revenue by segment segment’s not percentage negatively materially Asia-Pacific X but did the divestitures bottom impact line. affected the points,
and On Bloomington the The and EBITDA feel from we above the QX driven Asia-Pacific ibuprofen growth. remains XX% and our performed We shortage, portion Slide our reported we Bloomington an expectations clinical but product growth fastest Softgel divestitures important the EBITDA the historical substance, revenue Specialty revenue and revenue to by the about revenue partially good long-term is which performance business. of legacy our quarter. was segment X%, with the XX% revenue XX of $XXX.X growth growing percentage with October by period, translate during within our in Recent during points the XX continuously modest percentage Biologics acquisition, that, driven site into during the segment’s contributed and drug Specialty EBITDA to is business. and announcement acquisition business impact points this Delivery has growth growth the the Another quarter. of of quarter, in of segment the in item basis, drug would and saw up growth, with larger Biologics organic Biologics XX% and high-growth time quarter critical EBITDA business XXXX, and in comparable and segment X the Biologics segment XX% segment’s immediate segment which was million that prospects and shows Delivery reported note organic versus segment average. was Drug growth approximately continued Drug of growth of the for reported the in second to prior-year milestones strong offset normalized this project A of line of which closed European regarding in declines completion Catalent. growing strong in the by programs, investments the up have the
deliver to to Biologics our growth. continue We that business future is positioned well believe
mentioned, the suite and third online level its and John continues As complete is to Madison of ramp. utilization
nice the volumes favorable points to the business, segment’s of combination which respiratory we Specialty volume pipeline, programs a in of moved was our the million to growth one within quarter, revenue quarter, and volumes has the solids revenue percentage strong capacity by saw first-quarter by and increased a XX% a few US as this versus segment acquisition, increasing Softgel Biologics, of recovery Slide segment within higher In attractive we we sterile and performance during development including and that period, insight percentage EBITDA Delivery, saw during internal the in and have within and EBITDA and these technology mix Pharmaceuticals high-margin XX offsetting in which spay introductions, capacity to to being ophthalmic which unused segment provide during several addition one volumes recovery which quarter. accelerating increasing which for long-cycle and products of $XXX development discussed number The second the the XX Partially said, leverage during That well EBITDA a XX% contributed Fundamentals was comparable revenue reported see quarter. Delivery of experienced high-margin earnings in-house continue primarily quarter is Biologics the the our near Oral in Juniper decline into Oral In Analytical expect decline new Drug to included solids the disclosing with Technology, late-stage additional platforms. the midterm. call. the revenue shows oral decline businesses, for growth Delivery dry our our our of driven our and Drug customer second from the our key long-cycle as of strongest as points prior-year development fill Drug revenue product utilization levels. experienced segment of business, up to X% within in Services XX% business, oral X our which declines organic driven product growth are NPI, Development order remain NPIs.
marketing can we reminder, our of nor of or business are predict of indicators since the metrics these commercial a only sales products, these do the directional ultimate success them. we not control As
first XX, the first XX% XXXX, the above the and six $XXX December we six reported of development reported months development of small prior which million, across revenue revenue in ended molecule fiscal year. both is months the For large
is Additional our revenue, included accordance XXX, today now development ASC XX-Q disclosure filed our the in with Form in with on SEC. which is calculated
guidance expected introduced million XX financial we gives highlighted. fiscal contribute ability is the it us on in are confidence which $XX John important fiscal deliver year. the addition, which six NPIs of revenue This contribution revenue year, especially of of In the to than first new in fiscal double as the is more months our as in products our additional previously launched to XXXX prior
down Now, comparator treatment our the basis XX, activity as in the prior Clinical fiscal was second ASC quarter posted of compared net of revenue compared XXX XX% which shown basis driven to on by Services the Supply prior-year, segment sourcing on growth of slide revenue a to million, year. $XX.X
storage the XXX, ASC our due network. of cold distribution the revenue increased of segment mix to by the favorable the related and increased in product distribution Excluding growth XX% utilization increased across improved prior-year, Segment X% to services. and impact the storage compared driven revenue EBITDA second capacity cold volume primarily business, to quarter and services
segment organic. and revenue the was within recorded CSS of growth EBITDA All
segment’s important revenue disclosed note new our backlog is reference business a second X% is $XXX December CSS of during on to was and trailing business slide now that backlog of The next and reported times. I have segment revenue which XX-month compared figures change The ratio The wins the segment wins XXst, net net new quarter, It the net the net sequential As new million, XXXX, basis. been ASC the $XXX XXX the for a and the comparator include just information. for XX% an of business book-to-bill adjusted is X.X of increase prior-year. quarter increase. that million the accounting wins recorded contains in to
the Bloomington GAAP income reporting net or slide is format offset revenue as earnings the measure, from six of as of operating oral constant segment the distribution EBITDA are computation out figures month, Juniper I drivers won’t discussed assist solids already grace bridge the adjusted business acquisition by segments performance Slide growth are The the slide reported year-to-date consolidated is for Supply within next which for proximate certain which partially growth XX on cover shortage and key detailed shows operations high-margin to reconciliation the and of strong will declines Softgel last the statement products. XX due Slide storage both have presentation Pharmaceuticals, loss. slide. and We XX. drivers currency. and of various in tying This within impact increased the by to in most results. since XX the which a Biologics our precisely worldwide reported second of closely EBITDA, shown XX our revenue in our on in on parallel segment Services, quarter same provides they months results our the the Clinical ibuprofen and detail the
format. second quarter supplemental of slide the This a version a net a earnings adjusted year the non-GAAP $XX.X million. EBITDA adjusted also is Moving currency adjusted growth includes same EBITDA net XX, in of quarter On priorities. income diluted On essentially net ago. $XX.X the or this million EBITDA on Pharmaceuticals a slide the Juniper to compared detailed increased on by was in capital and slide. Slide seen allocation the back increased Biologics $X.XX more reconciliation that per you XX, adjusted of Most $XXX was summarize adjusted slide of or and see income acquisition. income million loss Bloomington of to reconciliation information capital X%. the can quarter vision the second and included driven table slide per end diluted to share deck the reconciliation $X.XX the A in share quarter shows as constant XX EBITDA at add our second shows section our X% or to second adjusted basis, net adjusted
leverage December times, the during is XX we and X.X of level which ratio in is reported from as times down history. modestly the Our Catalent’s full lowest X.X prior the was net quarter
transactions we XX. a of on is both the down our with and dollar-denominated August term our proactively And from As acquisition paid in Juniper million reminder, the loan the issue. US on closed proceeds impacts in leverage equity $XXX offering, July, reflected
of generation and three cash per year. adjusted a its free given and of a the company Additionally, one naturally company half EBITDA, the growing between turn decrease flow ratio strong of delivers the quarters
followed allocation focus organic our and on capital Finally, and M&A. by strategic unchanged first priorities growth, remain foremost
reaffirming XX, we are fiscal Turning for to guidance. year financial previously issued XXXX on our our slide outlook
in year of to expect full to continue billion billion. $X.XX the We range $X.X revenue
income EBITDA We expect of full $XXX million adjusted range the year to to million and in $XXX net million. full the of $XXX range $XXX adjusted year million in
fully expect million diluted XX expect to for of a XXX We of $XXX ending that the will basis XXX to on range in average fiscal shares. our year the and for we expenditures million capital the in million range be $XXX share weighted June count million
revenue, tax we we our guidance rate, to in year. be to expect and the to income, provided our we just wanted EBITDA related the addition XX% XX% which expectations between adjusted and In reiterate to also on effective adjusted net fiscal consolidated
XXXX million interest our in reflective $XXX approximately curve floating-rate July expect also as We to updated debt expense an fiscal million, be LIBOR to as which pay is for year both debt. down the $XXX of well
in the our year. highlight remind everyone our of me expected and let seasonality quarterly business through progression Additionally, the
EBITDA fourth any far, our fiscal far. our in the year XX% by expect where of by As for EBITDA be our the now quarter questions. first quarter year. with of half now, XXXX in is adjusted strongest XX% first and continue to Operator, year generally of year This open fiscal between of and the of to will adjusted like year the for we years to the case XX% fiscal quarter of we half would any being fiscal realize the to in lightest discussed XX% several call the the second our
